Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Market Closed 07-24 16:00:00 EDT

271.77

+3.03

+1.13%

盘后271.40

-0.37-0.14%

19:34 EDT

High275.58	Low265.64	Vol1.15M
Open268.74	D1 Closing268.74	Amplitude3.70%
Mkt Cap36.26B	Tradable Cap36.19B	Total Shares133.43M
T/O312.65M	T/O Rate0.86%	Tradable Shares133.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":271.77,"timestamp":1784923200000,"preClose":268.74,"halted":0,"volume":1151029,"hourTrading":{"tag":"盘后","latestPrice":271.4,"preClose":271.77,"latestTime":"19:34 EDT","volume":57569,"amount":15645529.056,"timestamp":1784936044742,"change":-0.37,"changeRate":-0.001361,"amplitude":0.00476},"delay":0,"changeRate":0.011274838133511843,"floatShares":133157589,"shares":133427910,"eps":4.0295005,"marketStatus":"Market Closed","change":3.03,"latestTime":"07-24 16:00:00 EDT","open":268.74,"high":275.58,"low":265.64,"amount":312646410.4786,"amplitude":0.036987,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.0295005,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":268.74,"preHourTrading":{"tag":"盘前","latestPrice":268.93,"preClose":268.74,"latestTime":"09:29 EDT","volume":730,"amount":197088.83099999998,"timestamp":1784899799999,"change":0.19,"changeRate":0.000707,"amplitude":0.012242},"postHourTrading":{"tag":"盘后","latestPrice":271.4,"preClose":271.77,"latestTime":"19:34 EDT","volume":57569,"amount":15645529.056,"timestamp":1784936044742,"change":-0.37,"changeRate":-0.001361,"amplitude":0.00476},"volumeRatio":0.9645713732716047,"impliedVol":0.5633,"impliedVolPercentile":0.9761},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"1157255621","title":"Earning Preview: Alnylam Pharmaceuticals Q2 revenue is expected to increase by 101%, and institutional views are mostly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1157255621","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1157255621?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:00","pubTimestamp":1784851210,"startTime":"0","endTime":"0","summary":"Abstract Alnylam Pharmaceuticals will report fiscal second-quarter 2026 results on July 30, 2026 Pre-Market; investors will focus on revenue momentum, profitability, and progress across core RNAi...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Alnylam Pharmaceuticals Q2 revenue is expected to increase by 101%, and institutional views are mostly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766070","title":"Alnylam Pharmaceuticals is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653766070?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:54","pubTimestamp":1784732040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 10:54 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750647","title":"Alnylam Pharma (ALNY) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750647?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:17","pubTimestamp":1784722657,"startTime":"0","endTime":"0","summary":"In a report released today, Kostas Biliouris from Oppenheimer maintained a Buy rating on Alnylam Pharma, with a price target of $500.00. Biliouris ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","PBE","GNMX","LU0889565916.HKD","BK4548","BK4139","LU0320765992.SGD","ALNY","BK4588","LU0882574055.USD","BK4127","BK4585","OPY","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653588837","title":"U.s. Research Roundup-danaher, Gm, Msci","url":"https://stock-news.laohu8.com/highlight/detail?id=2653588837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653588837?lang=en_us&edition=fundamental","pubTime":"2026-07-22 16:07","pubTimestamp":1784707645,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Danaher, GM, MSCIJuly 22 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, including Danaher, GM and MSCI on Wedn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4N43O0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMT","ANET","VHT","CVX","ADC","COF","AAT","XTN","XYZ","AKTS","BOKF","CALX","ICF","AFL","ALK","CPT","IYZ","KMX","ADP","CARG","ICOI","ACVA","DHR","SCHW","AMN","ABBV","AAOI","CVNA","CONY","ALLY","AA","CLDX","CLX","AGNG","CSR","MO","ABT","CHRW","COIN","CRCL","CMS","BEPC","FIAT","MMM","ICRC","BNY","ALNY","CLH","CVLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652236096","title":"Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2652236096","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652236096?lang=en_us&edition=fundamental","pubTime":"2026-07-18 10:17","pubTimestamp":1784341077,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) is drawing attention after advancing its Alzheimer’s disease pipeline by initiating a Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s and completing enrollment in a related cerebral amyloid angiopathy study.\nSee our latest analysis for Alnylam Pharmaceuticals.\nDespite the Alzheimer’s updates, Alnylam Pharmaceuticals’ share price has come under pressure, with the stock down 10.47% over the past week and 33.16% on a year to date share price...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4139","LU0889565916.HKD","PBE","ALNY","LU0109394709.USD","BK4585","LU0320765992.SGD","LU0114720955.EUR","BK4588","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144544066","title":"Movement Alert｜Alnylam Pharmaceuticals Falls 5.04% in Regular Trading, Trading at $268.73","url":"https://stock-news.laohu8.com/highlight/detail?id=1144544066","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144544066?lang=en_us&edition=fundamental","pubTime":"2026-07-18 02:37","pubTimestamp":1784313448,"startTime":"0","endTime":"0","summary":"On July 17, Alnylam Pharmaceuticals fell 5.04% in regular trading, trading at $268.73 USD/share, with Turnover of $174 million.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651186441","title":"Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2651186441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651186441?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:05","pubTimestamp":1784203500,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 16, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the sec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","ALNY","BK4588","PBE","LU0882574055.USD","BK4548","LU0889565916.HKD","LU0114720955.EUR","BK4139","BK4585","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441541","title":"Alnylam Schedules Conference Call on Second-quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441541?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:00","pubTimestamp":1784203216,"startTime":"0","endTime":"0","summary":"Alnylam schedules conference call on second-quarter 2026 resultsAlnylam schedules second-quarter results release for July 30, 2026, before the US market open.Management to host an earnings conference ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL3ZSSJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","LU0320765992.SGD","BK4588","BK4585","BK4139","LU0882574055.USD","LU0109394709.USD","PBE","BK4548","LU0114720955.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430205","title":"Alnylam Initiates Phase 2 Trial of Mivelsiran in Down Syndrome-associated Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430205?lang=en_us&edition=fundamental","pubTime":"2026-07-15 15:30","pubTimestamp":1784100618,"startTime":"0","endTime":"0","summary":"Alnylam initiates Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s diseaseAlnylam initiated a Phase 2 trial of mivelsiran in Down syndrome-associated early-stage Alzheimer’s disease, expanding its clinical Alzheimer’s program.Enrollment completed in the Phase 2 cAPPricorn-1 study of mivelsiran in cerebral amyloid angiopathy; initial results expected in 2028.Phase 1 mivelsiran data in early-onset Alzheimer’s showed no increased ARIA signal; mean maximum CSF reductions reached 89.9% for sAPPβ.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on July 15, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL797Ymk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU0889565916.HKD","BK4585","LU0114720955.EUR","LU0320765992.SGD","PBE","BK4548","LU0109394709.USD","ALNY","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651102563","title":"Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2651102563","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651102563?lang=en_us&edition=fundamental","pubTime":"2026-07-14 22:50","pubTimestamp":1784040635,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals'  Q2 financial results will be important in determining where 2026 revenue will fall within the guidance range and whether management would further refine that guidance, BofA Securities said in a note Tuesday.The investment firm said it remains bullish on the large commercial opportunity in transthyretin amyloid cardiomyopathy, but is taking a more conservative stance on the long-term opportunity pending details on the competitive dynamics.The firm's survey of cardiologists treating ATTR-CM patients has consistently shown that Amvuttra will continue to gain market share, though there has been variability in estimates of its share relative to stabilizers, according to the note.Analysts said they now expect longer Amvuttra net price erosion through 2031 as competitive and payor dynamics continue to impact price, and estimate potential peak sales in ATTR-CM across Amvuttra and nucresiran of $11.8 billion, down from $14.6 billion previously.BofA Securities kept its ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105476","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (MDGL) and Krystal Biotech (KRYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105476?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:40","pubTimestamp":1784032839,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY), Madrigal Pharmaceuticals (M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-madrigal-pharmaceuticals-mdgl-and-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-madrigal-pharmaceuticals-mdgl-and-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","XBI","KRYS","BK4581","PSCH","BK4139","BK4548","XLV","LABU","LU0889565916.HKD","LU0029874061.USD","LU0114720955.EUR","HELX","MDGL","LU0128526141.USD","PBE","HCSG","BK4137","BK4588","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651110312","title":"BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2651110312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651110312?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:10","pubTimestamp":1784031044,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has an average rating of overweight and mean price target of $444.35, according to analysts polled by FactSet.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651148003","title":"Alnylam Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651148003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651148003?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:57","pubTimestamp":1783958220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 11:57 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651100961","title":"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651100961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651100961?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:00","pubTimestamp":1783954842,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX), Vera Therapeutics (VERA) and A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XLV","LU2324357040.USD","LABU","LU0882574055.USD","HCSG","BK4581","LU0114720955.EUR","BK4585","ALNY","IMRX","LU0320765992.SGD","XBI","VERA","BK4548","LU0889565916.HKD","LU0128526141.USD","BK4563","LU0029874061.USD","PBE","BK4137","BK4588","BK4539","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150485682","title":"Movement Alert｜Alnylam Pharmaceuticals Falls 5.29% in Regular Trading, Trading at $281.53","url":"https://stock-news.laohu8.com/highlight/detail?id=1150485682","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150485682?lang=en_us&edition=fundamental","pubTime":"2026-07-13 22:17","pubTimestamp":1783952244,"startTime":"0","endTime":"0","summary":"On July 13, Alnylam Pharmaceuticals fell 5.29% in regular trading, trading at $281.53 USD/share, with Turnover of $117 million.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651120251","title":"Alnylam price target lowered to $410 from $505 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2651120251","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651120251?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:55","pubTimestamp":1783950942,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on Alnylam (ALNY) to $410 from $505 and keeps a Buy rating on the shares as part of a broader research note ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-410-from-505-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-410-from-505-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","LU0320765992.SGD","BK4588","BK4585","BK4139","LU0882574055.USD","LU0109394709.USD","PBE","BK4548","LU0114720955.EUR","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115035","title":"Alnylam Pharmaceuticals Inc : Truist Securities Cuts Target Price to $410 from $505","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115035?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:11","pubTimestamp":1783941105,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4139","LU0882574055.USD","PBE","BK4548","ALNY","LU0889565916.HKD","BK4585","LU0114720955.EUR","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650342491","title":"NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-07-10","url":"https://stock-news.laohu8.com/highlight/detail?id=2650342491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650342491?lang=en_us&edition=fundamental","pubTime":"2026-07-11 02:45","pubTimestamp":1783709120,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-07-10Nasdaq 100.NDXTop PerformersPercent ChangeMeta Platforms IncMETA.OQ+6.0%MercadoLibre IncMELI.OQ+4%NVIDIA CorpNVDA.OQ+3.5%Nebius Group NVNBIS.OQ+3.5%Sandisk CorpSNDK.OQ+3.0%Bottom PerformersPercent ChangeCrowdStrike Holdings IncCRWD.OQ-5.5%Fortinet IncFTNT.OQ-4.1%Alnylam Pharmaceuticals IncALNY.OQ-4.0%Palo Alto Networks IncPANW.OQ-3.9%Datadog IncDDOG.OQ-3.7%The Nasdaq 100.NDXgained 96.88 points, or 0.33%, to 29,823.69 and recorded no new highs and no new lows. 59 stocks rose and 43 fell as advancing issues outnumbered decliners by a about a 1.4-to-1 ratio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL8N43C1H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","IE00B19Z3B42.SGD","LU0070217475.USD","LU2471134952.CNY","LU1670627923.USD","IE0034235188.USD","07261","HK0000320223.HKD","LU2360106780.USD","LU2592432038.USD","COWG","ILDR","LU2242649171.HKD","IE0005OL40V9.USD","LU0048584097.USD","LU2357125470.USD","LU2491050071.SGD","CLOU","LU1712237335.SGD","LU0472753341.HKD","LU2552382132.HKD","IE00BFSS8Q28.SGD","LU1935043536.SGD","LU1951198990.SGD","META","NVDX","IE0034235303.USD","LU0072461881.USD","LU0957791311.USD","IE00B0JY6N72.USD","IE00B64PRP62.GBP","LU2191332357.HKD","GPIQ","LU0072462426.USD","LU1301847155.USD","LU2954938101.SGD","LU0053666078.USD","LU2063271972.USD","LU1244550494.USD","NVD2.UK","LU2272731600.USD","LU2404859667.USD","SNDK","LU0130102774.USD","NVDB","LU0823431647.USD","IE00B19Z8X17.USD","LU1868837565.USD","LU1815333072.USD","LU1923622291.USD","LU0823421333.USD","LU2361045086.USD","LU0082616367.USD","OGIG","LU1037948541.HKD","CNAV","NVIW.SI","LU1267930730.SGD","LU2249611893.SGD","LU1861127337.USD","LU2764263203.CNY","KMLI","LU1670628061.USD","LU2236285917.USD","NBIS","AIFD","QQQ","LU0154236417.USD","HK0000304805.HKD","LU1084165304.USD","LU2463028550.USD","LU1718418525.SGD","SGXZ31699556.SGD","BK4141","LU1861220033.SGD","LU0106261372.USD","FDTX","LU2764262908.HKD","LU0683600562.USD","PSQ","SG9999018857.SGD","BK4122","LU2347655156.SGD","SG9999014005.SGD","LU0133085943.USD","LU2089284900.SGD","LU0957808578.USD","LU1815336760.USD","NJUL","LU1814569148.SGD","IE000Q6AESB8.SGD","LU0106959298.USD","SGXZ23171101.USD","LU1839511570.USD","LU2097344357.USD","LU0061474705.USD","LU1935042488.USD","LU1721428933.USD","IE00BKDWB100.SGD","LU2860962120.EUR","QID","METU","CNEQ","SG9999015341.SGD","LU1429558221.USD","LU2092937148.SGD","AIPI","IE00B4JS1V06.HKD","SGXZ99366536.SGD","LU0320765489.SGD","07522","LU0323239441.USD","LU0109391861.USD","LU1116320901.HKD","LU0187121727.USD","LU0787776722.HKD","HK0000914660.USD","IE00B19Z9Z06.USD","PANW","LU0868494617.USD","LU2111349929.HKD","BK4588","LU1400636574.HKD","NVDU","ANV","IE00BMPRXQ63.HKD","LU0726765562.USD","WCLD","SNPE","RSPC","CRWD","LU1861220207.SGD","LU1868837136.USD","LU0251132253.USD","METW","GB00BDT5M118.USD","LU1116320737.USD","LU1127390331.HKD","LU2506951792.HKD","BK4607","FSMD","GB00B4LPDJ14.GBP","IE0034235295.USD","LU2543165471.USD","IE00BKPKM429.USD","LU0648001328.SGD","SG9999014914.USD","SG9999014542.SGD","LU0077335932.USD","BK4524","LU0456842615.SGD","LU1988902786.USD","SG9999018865.SGD","LU0329931173.USD","IE0004445239.USD","LU1169589451.USD","BK4023","LU1803068979.SGD","LU1861215975.USD","03034","LU1691799644.USD","LU2361044949.HKD","LU0444971666.USD","LU2491050154.USD","SMH","SNXX","IE00BGHQF748.EUR","LU0868486357.SGD","LU1868837300.USD","LU2326559502.SGD","LU1923622614.USD","LU0642271901.SGD","LU2237443895.HKD","LU0079474960.USD","LU2294711713.HKD","SCHA","NULC","LU1861558580.USD","SNDU","IETC","WCBR","LU0203345920.USD","SGXZ51526630.SGD","SG9999014559.SGD","LU2272731782.SGD","LU0256863811.USD","LU0784383803.USD","SG9999000418.SGD","BK4612","LU0345769631.USD","LU0690374961.EUR","FBYY","LU0211331839.USD","LU2028103732.USD","LU2125154778.USD","LU2125909247.SGD","QDEC","LU2097829019.USD","DAT","LU0417517546.SGD","LU1917777945.USD","LU0353189680.USD","LU1934455194.USD","07266","BK4548","LU2404859741.USD","BK4614","USD","SOXQ","LU0545039389.USD","IE00BGV7N243.SGD","LU2065170008.USD","LU2083900584.USD","METD","LU0070302665.USD","SHOC","IE00B8HQ1Z84.USD","LU1153585028.USD","LU0965509010.AUD","LU0476273544.USD","LU2417539215.USD","LU2505996681.GBP","LU2461242641.AUD","XLK","LU0719512351.SGD","LU0289960550.SGD","LU1551013425.SGD","LU2637965513.SGD","LU0965509101.SGD","LU0708995401.HKD","IXN","METV","LU0061474960.USD","LU1400636491.USD","LU1066051225.USD","IE0009356076.USD","LU0557290698.USD","LU0985489474.SGD","LU2420271590.USD","LU0823434583.USD","HK0000914686.HKD","LU1633808545.USD","LU2272731865.HKD","LU0861579265.USD","LU2462591350.SGD","LU0174119429.USD","LU1868836591.USD","09086","GB00B4QBRK32.GBP","LU1564329461.SGD","LU0225283273.USD","LU1732799900.SGD","LU1852331112.SGD","NVDS.UK","IE00BN0W2T93.GBP","VT","CIBR","LU0029864427.USD","LU0889565916.HKD","LU1629891620.HKD","LU1778281490.HKD","LU2077746001.SGD","LU0211328371.USD","LU0107464264.USD","FBY","FCOM","HK0000306685.HKD","LU0316494557.USD","IE00BJJMRX11.SGD","LU2097344431.USD","LTL","IE0009G5SDU7.USD","LU2106854487.HKD","DOGD","BK4561","FBL","LU2047632596.USD","IE00B3SWFQ91.USD","BK4613","LU2552382215.SGD","SQQQ","LU1697837992.HKD","DIPS","NVDL","LU2133065610.SGD","LU2265009873.SGD","LU1035775433.USD","CLSE","LU1400636657.SGD","SG9999002224.SGD","LU2896262040.SGD","LU1003077747.HKD","LU1323610961.USD","LU1983260115.SGD","LU2413666699.HKD","LU2462157665.USD","LU0949170426.SGD","LU0109392836.USD","LU0795875169.SGD","SCHM","LU2092627202.USD","LU0158827781.USD","VGT","LU0345768740.USD","LU1435385759.SGD","LU2286300806.USD","IE00BYXW3230.USD","LU0820561909.HKD","TQQY","TQQQ","BK4534","LU1066053197.SGD","LU2168564222.USD","IE00BHPRN162.USD","IE00BQXX3C00.GBP","LU1868836914.USD","LU2602419157.SGD","LU0175139822.USD","LU2089985449.USD","LU2100268510.USD","LU0724617625.USD","LU2211815571.USD","LU0006306889.USD","NEBX","LU1242518931.SGD","LU1934455277.USD","BK4528","07568","LU0215105999.USD","LU1823568750.SGD","LU1935042991.SGD","09834","NVDQ","LU0985320562.USD","IE00BD6J9T35.USD","HK0000320264.USD","LU1642822529.SGD","BK4579","LU1699723380.USD","NVD","LU2237443622.USD","BK4097","BK4598","LU1119994496.HKD","LU1861559042.SGD","SG9999001077.SGD","LU2430703178.SGD","TTEQ","NVDO","BK4220","IE000KEQY171.SGD","SNDG","IE00BQXX3F31.USD","CLOD","IE00B7SZLL34.SGD","LU2065169927.USD","LU2095319765.USD","LU0203201768.USD","LU0823414551.USD","LU2125909916.SGD","SG9999014880.SGD","LU0114720955.EUR","IE0002270589.USD","LU2247934214.USD","SG9999014906.USD","LU0820561818.USD","LU0276348264.USD","LU2381873111.SGD","PALD","LU0323591593.USD","IE00BJLML261.HKD","LU2317271919.USD","3NVD.UK","LU0354030438.USD","LU2360107671.USD","LU0784385840.USD","LU1551013342.USD","IE00BZ1G4Q59.USD","TEK","LU1914381329.SGD","LU0528227936.USD","LU2242650005.HKD","SPAM","LU2125909759.SGD","LU2473716301.USD","USXF","LU2168564495.EUR","BK4533","IE0004091025.USD","IE00BZ199S13.USD","LU2264538146.SGD","IE00BMPRXN33.USD","LU1064131342.USD","LU2279701549.SGD","HK0000819398.USD","LU2054465674.USD","MELI","OPTZ","BK4560","LU1670710661.SGD","LU0345769128.USD","IE00BN29S564.USD","LU2750360641.GBP","LU0390134368.USD","BK4507","LU0080751232.USD","LU2148611432.USD","LU2237957811.SGD","LU1066051811.HKD","LU2756315664.SGD","WISE","IE0004086264.USD","LU2458330243.SGD","LU0878866978.SGD","LU0256863902.USD","LU0689626769.HKD","LU1868837722.USD","LU2322448957.HKD","ALNY","SG9999014575.USD","LU2471134523.USD","NDX","LU2355687059.USD","LU2999663052.SGD","LU0882574139.USD","SG9999015952.SGD","NVDW","LU2087621335.USD","IE00BFSS7M15.SGD","IE00B775SV38.USD","LU2087625088.SGD","LU1496350502.SGD","LU1244550221.USD","LU1934455863.HKD","LU2168564065.EUR","ARTY","SMHX","IE0001KFT4U8.USD","LU0149725797.USD","LU2168563687.JPY","LU0210533765.USD","SOXX","SGXZ81514606.USD","IHAK","LU1974910355.USD","LU2462591277.SGD","LU0963586101.USD","ABFL","LU0096362180.USD","03086","IE0003U64NQ7.SGD","LU1674673691.USD","LU2290526834.HKD","LU0882574055.USD","LU2168564149.EUR","LU0823431563.USD","LU0289961442.SGD","LU0823414478.USD","LU2023251221.USD","SG9999014021.USD","LU0210528500.USD","LFGY","IE00B3M56506.USD","BK4139","IE00BWXC8680.SGD","LU0127658192.USD","JGRO","LU0069063385.USD","LU1880398554.USD","QQQG","IE00B8L5B284.USD","IGV","SG9999015358.SGD","LU0868494708.USD","IE00B775H168.HKD","LU0274383776.USD","BK4585","BK4581","NBIL","LU1074936037.SGD","SG9999015986.USD","IE00BDCRKT87.USD","IE00B5949003.HKD","LU0265550359.USD","IE00BDRTCR15.USD","LU0354030511.USD","LU2452424414.USD","IE00BKVL7J92.USD","LU0784384876.USD","LU1242518857.USD","SG9999001424.SGD","FAI","SG9999014039.USD","LU0308772762.SGD","LU2430703251.USD","LU1861217088.USD","LU1989772840.SGD","LU0347712357.USD","LU0979878070.USD","LU2237443382.USD","HK0000306701.USD","LU0329931090.USD","PTF","BUG","SG9999004303.SGD","LU2471134796.USD","LU0784385170.HKD","LU1201861249.SGD","BK4592","LU0553294199.USD","LU2746668461.USD","IE000W1ABFV2.USD","BK4566","LU0109394709.USD","LU0094547139.USD","LU0823421416.USD","LU1720051108.HKD","PANG","HXC","LU1989764664.SGD","LU1989764748.USD","LU1316542783.SGD","LU1202635105.USD","IE00B0169N27.USD","NVDS","FTNT","LU0289739343.SGD","LU0353189763.USD","IE000YTNTUN2.SGD","LU2125909593.SGD","LU0096364046.USD","PBE","LU0823434740.USD","SG9999015945.SGD","BK4503","BK4535","SNDC","LU0942090050.USD","LU1280957306.USD","IE00B19Z9P08.USD","BK4587","LU0158827948.USD","LU0342679015.USD","BK4605","LU0050427557.USD","SG9999017495.SGD","LU0143551892.USD","LU2430703095.HKD","LU0081259029.USD","LU0738911758.USD","LU0795875086.SGD","LU2347655073.USD","LU1046421795.USD","IE000ITXATA3.USD","LU1496350171.SGD","IE00BN0W2V16.EUR","07788","LU0444973449.USD","LU2023250330.USD","LU0210536198.USD","LU1571399168.USD","PALU","ONLN","LU0786609619.USD","LU0138981039.USD","BK4529","LU2210150020.SGD","SOXY","LU1145028129.USD","ESUM","LU0672654240.SGD","SG9999014013.SGD","LU2237443465.HKD","LU0208291251.USD","IE00BK4W5M84.HKD","LU0310799852.SGD","LU0157215616.USD","FCUS","LU0234572021.USD","LU2471134879.HKD","LU0143863198.USD","LU0203202063.USD","LU2458330169.SGD","NAPR","HK0000304797.USD","NDAQ","LU2244417387.USD","LU1069344957.HKD","LU2237438978.USD","LU1720051017.SGD","LU1645745479.HKD","LU2125154935.USD","LU0143863784.USD","LU1935042215.USD","NVD3.UK","LU0708994859.HKD","LU0912757837.SGD","QLD","07388","LU1923623000.USD","LU0690374615.EUR","LU2065171402.SGD","LU0494093205.USD","02834","LU1232071149.USD","IE00B19Z8W00.USD","IE00BJTD4V19.USD","LU0011850046.USD","LU0265550946.USD","NOCT","LU1670756490.USD","LU0823411888.USD","LU0203347892.USD","SG9999014567.USD","BK4609","IE00B7KXQ091.USD","IE00BMPRXR70.SGD","LU1235294995.USD","LU0788109477.HKD","LU2360107168.USD","LU1868838027.USD","LU2357305700.SGD","QQQM","BK4112","LU0314104364.USD","LU3102509885.SGD","LU1169590202.USD","CHAT","LU0552385451.USD","IE00BJJMRY28.SGD","LU0348723411.USD","LU0965509283.SGD","LU1951200564.SGD","LU0965508806.USD","CRWL","IE00B894F039.SGD","LU1935043023.USD","LU1261432733.SGD","LU0949170772.SGD","LU0162691827.USD","LU1992135399.USD","IE00BJTD4N35.SGD","LU2720916845.USD","LU0097036916.USD","BK4527","LU0532187761.SGD","LU2491049909.HKD","LU0980610538.SGD","03455","QMAR","LU2237957902.USD","IE00B3QW5Z07.USD","IE00BK4W5L77.USD","LU1548497426.USD","NVDG","NVDY","BK4551","LU0128525929.USD","LU1989772923.USD","LU2764263039.SGD","LU1564329628.SGD","LU2322448791.USD","SPTE","IE0008368304.USD","LU1244550577.SGD","LU0320765992.SGD","IE00B19Z3581.USD","LU1732800096.USD","TYLG","SNDQ","LU0889565833.HKD","LU1489326972.SGD","HK0000532082.HKD","LU0943347566.SGD","IE00BN0W2W23.USD","TMSL","DDOG","SOCL","LU0640476718.USD","2NVD.UK","LU0531971165.HKD","LU0238689110.USD","LU0661504455.SGD","LU2552382058.USD","NVDA","NJAN","LU1267930573.SGD","LU2433249047.HKD","QQQX","LU1623119135.USD","XLC","LU0068578508.USD","LU0345770308.USD","IE0004445015.USD","LU0056508442.USD","LU2750360997.AUD","LU0689472784.USD","LU0511384066.AUD","LU2746668974.SGD","BK4543","LU0310800379.SGD","LU1366333091.USD","LU1059921491.USD","LU1366192091.USD","LU1670711123.USD","ROM","LU2756315318.SGD","IE00BZ9MQY76.HKD","IE00B3S45H60.SGD","LU1670711040.USD","LU1791710400.SGD","NVII","SG9999002232.USD","LU1564329115.USD","TRFK","LU1670710588.SGD","LU2931357623.SGD","LU0345768153.USD","LU1564329032.USD","LU1674673428.USD","BK4549","SG9999014898.SGD","AGOX","LU0210535034.USD","LU0964807845.USD","BCDF","LU0466842654.USD","LU2361044865.SGD","NBIG","LU0170899867.USD","LU2505996509.AUD","LU1821325948.USD","IE00B1BXHZ80.USD","LU0211327993.USD","LU0267386448.USD","IE00B1B80R65.USD","LU0057025933.USD","LU0054578231.USD","LU1992135472.HKD","LU2089283258.USD","LU2456880835.USD","LU0124676726.USD","BK4554","LU2394011477.USD","IE00B19Z9505.USD","LU2237443549.SGD","IE00B1XK9C88.USD","LU0198837287.USD","NVYY","LU1037948897.HKD","NBIZ","LU2213496289.HKD","BK4170","LU2023250504.SGD","LU2108987350.USD","LU2487616109.SGD","LU0431992006.USD","XDAT","LU1066051498.USD","LU2023250843.SGD","LU0061475181.USD","LU0266013472.USD","LU2413666426.HKD","LU2210149790.SGD","FTEC","BK4077","BK4608","NVDD","PSWD","LU0950373646.USD","LU0234570918.USD","LU2271345857.HKD","LU0053687314.USD","IE00B4YYXB79.USD","LU2237443978.SGD","SNVD.UK","SG9999015978.USD","LU1791710582.SGD","LU2360032135.SGD","LU2403377893.USD","LU0820562030.AUD","BK4567","LU2250418816.HKD","BK4550","LU0345770993.USD","EFIV",".IXIC","LU2065171311.SGD","VOX","BK4532","LU1880398471.USD","LU0320765059.SGD","LU0433182093.SGD","LU1267930490.SGD","LU1868836757.USD","LU0323240290.USD","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184780518","title":"Movement Alert｜Alnylam Pharmaceuticals Falls 5.08% in Regular Trading, Trading at $296.89","url":"https://stock-news.laohu8.com/highlight/detail?id=1184780518","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184780518?lang=en_us&edition=fundamental","pubTime":"2026-07-11 00:52","pubTimestamp":1783702377,"startTime":"0","endTime":"0","summary":"On July 11, Alnylam Pharmaceuticals fell 5.08% in regular trading, trading at $296.89 USD/share, with Turnover of $334 million.Within the Biotechnology sector where Alnylam Pharmaceuticals belongs,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650113347","title":"Alnylam Pharmaceuticals is Maintained at Equal-weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650113347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650113347?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:56","pubTimestamp":1783691760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings(END) Dow Jones NewswiresJuly 10, 2026 09:56 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALNY","BK4588","LU0109394709.USD","PBE","LU0320765992.SGD","LU0882574055.USD","LU0889565916.HKD","BK4548","BK4585","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":-0.0758},{"period":"3month","weight":-0.1105},{"period":"6month","weight":-0.2408},{"period":"1year","weight":-0.1714},{"period":"ytd","weight":-0.3166}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.652174,"avgChangeRate":0.09805},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}